Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 1, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, February 28, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Robert Burns Maintained (YMAB) at Strong Buy with Decreased Target to $63 on, Feb 28th, 2022
Robert Burns of HC Wainwright & Co., Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Strong Buy with Decreased Target from $68 to $63 on, Feb 28th, 2022.
Robert has made no other calls on YMAB in the last 4 months.
There is 1 other peer that has a rating on YMAB. Out of the 1 peers that are also analyzing YMAB, all agrees with Robert's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $27 on, Monday, January 3rd, 2022
